Determining the N-Glycan and Collagen/Extracellular Matrix Protein Compositions in a Novel Outcome Cohort of Prostate Cancer Tissue Microarrays Using MALDI-MSI
- PMID: 39347566
- PMCID: PMC11600299
- DOI: 10.1158/2767-9764.CRC-24-0152
Determining the N-Glycan and Collagen/Extracellular Matrix Protein Compositions in a Novel Outcome Cohort of Prostate Cancer Tissue Microarrays Using MALDI-MSI
Abstract
Using matrix-assisted laser desorption/ionization mass spectrometry imaging techniques on a unique cohort of prostate cancer tissues, we highlighted several molecular characteristics of matrix that have potential to act as early predictors of prostate cancer metastasis.
©2024 The Authors; Published by the American Association for Cancer Research.
Conflict of interest statement
K. Bejar reports grants from National Center for Advancing Translation Sciences of Health under Award Number T32TR004545 outside the submitted work. R.J. Leach reports grants from NIH and American Cancer Society during the conduct of the study, as well as grants from NIH and American Cancer Society outside the submitted work. R.R. Drake reports grants from NIH during the conduct of the study, as well as reports that his laboratory is part of a Bruker-MUSC Center of Excellence in Clinical Glycomics program. Bruker, a mass spectrometry company, does not provide direct funds for research to R.R. Drake’s laboratory. They offer software and instrumentation maintenance support with the intent to develop new assays in the clinical glycomic field. The data presented in the manuscript were obtained on Bruker mass spectrometers, instruments that were purchased by R.R. Drake’s laboratory and/or institution. No disclosures were reported by the other authors.
Figures







References
-
- NIH . Cancer stat facts: prostate cancer [Internet]. 2022[cited 2022 Oct 10]. Available from:https://seer.cancer.gov/statfacts/html/prost.html.
-
- Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. . Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9. - PubMed
-
- Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910–4. - PubMed
-
- Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 2006;68:593–8. - PubMed